Pfizer has discontinued the manufacture and sale of its drug ‘Corex’ with immediate effect. The company is exploring all available options at its disposal. This step has been taken after Government of India (GoI) through its notification dated March 10, 2016, prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate + Codeine Syrup with immediate effect.
The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. Corex recorded a sale of Rs 176 crore for the nine months period ended December 31, 2015. Corex has a well-established efficacy and safety profile in India for more than 30 years. The company makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex Cough Syrup.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: